



LSX | WORLD CONGRESS

BIOTECH · HEALTHTECH · MEDTECH

PARTNERING, STRATEGY & INVESTMENT FOR
LIFE SCIENCE EXECUTIVE LEADERS

8th Annual

In-person

10-11 May 2022

133 Houndsditch, Liverpool St London, UK

Virtual

16-20 May 2022

www.lsxleaders.com/world
#LSXWorld @lsxleaders

Organised by: **LSX** | The network for life science executive leaders

LSX World Congress

10-11 May 2022

LSX World Congress

For the last 7 years, the LSX World Congress has been bringing together the executives that matter to the future of healthcare and life science strategy, investment, partnering and deal making.

LSX World Congress gathers the founders and CEOs of innovative start-ups through to publicly healthcare giants, and everyone in between. It represents the breadth and depth of the cutting-edge research and technology driving the advances in the industry right now and in the near future.


The biotech, healthtech and medtech industry's c-suite will be joined by the sector's most active investors, pharma and health technology BD&L teams, R&D leaders, KOLs and top tier service companies who are driving the sector forward.

In an industry as dynamic as this, LSX World Congress brings together

the people who are developing technologies, solutions and new business models to tackle the biggest healthcare challenges in the industry today, and helps answer the question; what's next and how do we get there?

With our relentless focus on quality peer-to-peer discussion, high-level networking and partnering, intimate conference formats and a vetted, high-calibre audience, we help you **Connect with Purpose™**

We are delighted to be returning to a physical event in 2022, with an additional virtual partnering week. It will include everything everyone has come to know and love about the Congress and continue to focus on **Biotech**, **Medtech** and **Healthtech** Leaders.



www.lsxleaders.com/world

#LSXWorld @lsxleaders

Contents

I'm interested in:

Jump to the right section

Who attends	click here
Why attend	click here
Our Partners	click here
Biotech Content	click here
Healthtech Content	click here
Medtech Content	click here
Networking Opportunities	click here
Delegate Packages	click here
Sponsorship Packages	click here
2021 Stats	click here

For full details please visit: www.lsxleaders.com/world

Who attends?

Biotech

Drug discovery, pre-clinical, clinical & on-the-market therapeutics

Medtech

Devices, surgical, diagnostics, implantables

Healthtech

Digital health, DTx, deep tech, databases, applications, wearables

Commercial Leaders

Big Pharma, Big Medtech, Big Tech

Investors

Angel, VC, CVC, Family Office, PE, Institutional

Advisors & Solution Providers

Consultancy, Professional Services, Contract Services, IP & Law, Investment Banks & Financial Services, PR/IR


Healthcare Industry Stakeholders

Academia, TTOs, Payers, Providers, Reimbursors



Who attends?

1000+ people will attend the 2022 LSX World Congress. They break down as follows:



Why attend?

You won't want to miss the 2022 LSX World Congress.

- 1000+ life science executives return, in-person, to London!
- 1,000s of 1:1 partnering meetings facilitated by our state-of-the-art event app and partnering system
- Hear from 200+ speakers from the world's leading life sciences and healthcare companies, investors, pharma and commercial leaders
- World-class content covering funding and financing, partnering and deal-making, capital deployment and commercialisation and product design and development across biotech medtech and healthtech.
- Join 450+ life science and healthcare C-suite executives across biotech, medtech and healthtech
- Meet 100+ of the world's leading pharma companies, big Medtechs and commercial leaders
- Connect with 350+ active global investors from angels and early VC through to institutional and public equities investors, and everyone inbetween
- Source and find the most innovative start-ups and growing companies with 75+ live showcase presentations
- Peer-to-peer learning and industry-leading expert advice through with breakout workshops, CEO Forums and tailored bootcamps

LSX World Congress is the leading strategy, investment, partnering and commercialisation event for life science executive leaders. It's back, and **it's LIVE!**

Partners

Platinum partners



Knowledge partner



Gold partners



Pharma Digital partner



Chinese Access partner



Silver partners




Bronze partners




Supporting partners



Floor plan



Biotech Leaders



BIOTECH LEADERS

Capital Markets & Investment


Partnerships & Deal-Making

Capital Deployment & Commercialisation Strategy

Biotech Speakers




Matthias Müllenbeck
SVP, Head Global BD & Alliance, Merck KGaA



Christian Dillon
CSO, Phoremest



Werner Lanthaler
CEO, Evotec



Sofia Håkansson Buch
VP Cell Therapy CMC & Manufacturing, Novo Nordisk



Stephanie Sirota
Partner and CBO, RTW Investments



Khaterah Ahmadi
Head of S&E Team, European BD&L Hub, MSD



Tim Luker
VP Venture Science, Corporate BD, Eli Lilly



Francis Pang
VP Global Market Access, Orchard Therapeutics




Bill Haynes
Head of Novo Nordisk Research Centre Oxford, Novo Nordisk



Tom Shepherd
CEO, Captor Therapeutics




Abie Eakangaki
Vice President, Statistical Consulting, Premier Research



Sofia Ioannidou
Partner, Andera Partners



Edward van Wezel
Managing Partner, BGV



Bonnie Van Wilgenburg
Principal, Monograph Capital Partners



Yuehua Cong
Head of Europe, Simcere Pharmaceutical Group



Maria Dahl
COO and Head of Europe, Innovent Bio



Roel Bulthuis
Managing Director, INKEF Capital



Priya Mande
CEO, PsiOxus Therapeutics



Mehdi Ainouche
Principal, Jeito



Anne Horgan
Partner, Cambridge Innovation Capital



Alexandra Zemp
Partner, McKinsey



Cody Powers
Principal - Portfolio & Pipeline, ZS Associates



Ben Hohn
Principal - Pharmaceuticals & Biotech, ZS Associates



Elisa Petris
Partner, Syncona


Biotech Speakers




Pierre-Louis Joffrin
CDO, Mogrify




Chris Rowe
Innovation Lead, Innovate UK



Matt Cardinal
VP Strategy & Program Leadership, Halloran



Graziano Seghezzi
Managing Partner, Sofinnova



Igor Rudychev
VP Enterprise Analytics, Horizon Therapeutics



Isabella Schidrich
Senior Managing Director, Nasdaq



Nigel Sheail
Global Head of M&A and BD&L, Novartis




Peter Llewellyn-Davies
CEO, invIOs



Simon Basham
Head of Cyber & TMT Broking UK, WTW



Robin Bhattacharjee
CEO, Actimed Therapeutics



Andrew Hack
Managing Director, Bain Capital Life Sciences




Sven Kili
CEO, Antion



Ulrica Slåne Bjerke
CIO, Arctic Aurora LifeScience




Tara Raveendran
Head of Healthcare & Life Sciences Research, Polar Capital



Andrew Udell
President, North America, Calliditas Therapeutics



Michael Altorfer
Chief Executive Officer, Swiss Biotech Association



Anita Meiklejohn
Principal, Fish & Richardson



Sally van Kooten
VP Commercial Strategy, KalVista Pharmaceuticals



Viola Bronsema
CEO and Secretary General, BIO Deutschland




John Dawson
Director, Oxford Biomedica



Ian Coyne
Executive Director Global Information & Intelligence, Coulter Partners



Deborah Harland
Partner, SR One



John Rudy
Member, Mintz



Markus Kalousek
Global Head Search & Evaluation, Novartis

Biotech Speakers



Suzanne Dilly
CEO, ValiRx



Steven Powell
CEO, eTheRNA




Robbie McLaren
Partner, Latham & Watkins



Jukka Muhonen
Director of Global BD & Alliance Management, Orion Corporation



Graham Defries
Partner, Goodwin



Tej Panesar
Investment Director - Life Sciences, British Patient Capital




Steven Harris
Chairman, CS Pharmaceuticals



Brad Robling
VP, Lilly Ventures, Corporate BD, Eli Lilly




Asaf Homossany
Senior Managing Director - EMEA, Nasdaq




Ed Saltzman
Head, Biotech Strategy, Lumanity




Rhoda Steel
Head of Community Impact, Johnson & Johnson UK




Wen Hwa Lee (He/him)
CEO and Chief Scientist, Action Against AMD



Pnina Weitz
Global Head of Venture Capital BD & Relationship Management, Lonza



Anna Williamson
Senior Director, Business Development, Roche



Brian Heaphy
SVP, Corporate Development, BMS



Kieran Rooney
VP, Strategic Alliances and Licensing, Amryt Pharma



Pierluigi Paracchi
CEO & Co-founder, Genenta Science




Nicklas Westerholm
CEO, Egetis Therapeutics




Jasper Bos
General Partner, Forbion; CEO, Forbion European Acquisition



Anette Steenberg
CEO, Medicon Valley Alliance



Jim Polson
Managing Director, FTI Consulting



Dima Kuzmin
Managing Director, 4BIO Capital



Marta Helena Lesko
Head of BD Enabling Technologies, Merck KGaA



Maya Khurana
Health and Life Sciences Director, Oliver Wyman

Biotech Speakers



Regina Hodits
Managing Partner, Wellington Partners



Ros Deegan
CEO, OMass Therapeutics



Erik van den Berg
CEO, AM Pharma




Valerie Vanhooren
CEO & Co-Founder, ONA Therapeutics




Andrew Hill
Product Innovation Lead, WTW



Patrick Hughes
Director, Advisory Services EMEA, Nasdaq



Alex Hamilton
Partner, Syncona



Jason Foster
CEO, Ori Biotech



Catherine Isted
CFO, ReNeuron



Donald Xu
Managing Director, Lynx Capital



Renee Aguiar-Lucander
CEO, Calliditas Therapeutics




Jean-Philippe Combal
CEO, Vivet Therapeutics



Lucas de Breed
Founder, August



Madeleine Armstrong
News Editor, Evaluate



Bernd Boidol
CEO, Proxigen




Marc Ramis Castellort
Venture Partner, Chasing Science



Jason Mellad
CEO, Start Codon



João Siffert
CEO & President, Design Therapeutics



Chris Chamberlain
Executive Director Experimental Medicine, AstraZeneca



Giuseppe Mazza
CEO, Engitix Therapeutics



Nanna Lüneborg
General Partner, Forbion



Beth Fordham-Meier
VP, Business Development, BioConsulting, Lumanity



Rebecca Pope (she/her)
UK Digital & Data Science Innovation Lead, Roche Products



Angela Drew
Director Regulatory Strategy, Premier Consulting

Biotech Speakers



Mark Dorff
Partner, Brown Rudnick



Nicki Thompson
CEO, Amphista Therapeutics



Maina Bhaman
Partner, Sofinnova Partners



Arthur Sands
CEO, Nurix Inc.



Piers Morgan
CFO, Cellcentric



Marcel Zwaal
CEO, Gadeta



Klaas Zuideveld
CEO, Versameb



Anton Mat
Director of Business Development, ISA Pharmaceuticals



Fredrik Johansson
CFO, Calliditas Therapeutics



Johan Strömquist
CEO, NDA Group




Björn Carlsson
Principal Consultant & Advisory Board Member, NDA Group



Andrew Roddam
CEO, Our Future Health



Jette Cowan
Head of Commercial – Pharmaceuticals, RSSL



John Cassidy
Investment Director Life Sciences & HealthTech, Softbank Vision Fund



Stephanie Léouzon
Partner, Torreyia



Guy Martin
Deputy Editor, Pharma Letter



Nach Dave
VP Development Strategy, Premier Research



James Halstead
Partner, Covington & Burling



Sarah Cowlshaw
Partner, Covington & Burling



Guy Dingley
Partner, Covington & Burling




Morag Peberdy
Of Counsel, Covington & Burling



Rachel Moss
Partner, McKinsey



Sara Secall
Partner, Invenergy



Victoria Darbyshire
Equity Analyst, J.P. Morgan


Biotech Speakers



Nick Pattinson
Head of Product, Automata



David Crome
Managing Director Compliance UK, ProPharma Group



Lala Gregorek
Healthcare Analyst, Trinity Delta



Franc Gregori
Analyst, Trinity Delta



Andrew Harrow
Partner, Goodwin



Martin Pfister
Principal, HTGF



Tahera Kan
VP Transactions, Johnson & Johnson Innovation EMEA, Johnson & Johnson



Tim Morris
COO/CFO, Humanigen



Hayley French
Investor, Vesalius Biocapital Partners

Biotech Agenda

Tuesday, 10 May – Main Agenda

09:00 LSX Welcome Address

09:05 Biotech in 2022: Another wave or a low tide?

- Review the 2021 biotech year in numbers: How much funding did the sector attract? How did the IPO market evolve? What are trends on the stock market?
- Deep-dive on external innovation: How do we see external innovation landscape evolve? What assets and companies are most successful?
- Looking ahead: What does this mean for 2022 and beyond?

Alexandra Zemp, Partner, McKinsey
Rachel Moss, Partner, McKinsey

09:30 The Next Phase Of Europe's Booming Biotech Ecosystem – Building Global Biotech Leaders, Financing Next Wave Innovation And Joining The Dots Between Clusters

After the shock in early 2020, the biotech ecosystem rebounded quickly and Europe was very much at the forefront of solving a the biggest global challenge in decades. As we enter the post-pandemic era, the European ecosystem has never been stronger with more capital, talent and experience and an ever-growing and more robust balance of early, growth and established companies. Executives of Europe's leading life biotech companies, investors and key stakeholders discuss the next phase, working in a pan-European collaborative strategy to translate innovation, and continue to strategically build an ever-stronger globally competitive powerhouse.

- How and why has Europe survived and thrived? What are the next steps for continued sustainable growth of the whole ecosystem?
- Is access to talent and experience to drive companies becoming easier with the move to a more digital world with amounts of remote working?
- Accessing the US market and building a transatlantic footprint is still ever critical, but in what ways is Europe leading the way?
- With more capital in the space, both with larger private investment rounds and on the buoyant public markets, are companies able to build a longer-term vision? Has there been a cultural shift?

Moderator: **Mark Dorff**, Partner, Brown Rudnick
Werner Lanthaler, CEO, Evotec
Brad Robling, VP, Lilly Ventures, Corporate BD, Eli Lilly
Debbie Harland, Venture Partner, SROne
Andrew Hack, Managing Director, Bain Capital Life Sciences
Graziano Seghezzi, Managing Partner, Sofinnova
Nanna Lüneborg, General Partner, Forbion

Biotech Agenda

10:30 Morning Break

CAPITAL MARKETS & INVESTMENT

11:00 Leading The Way In The Global Investment Landscape - New Strategies, Competition And Syndication

The numbers paint a picture of a booming investment market but the how, where and why of this capital influx are nuanced. And while total deal values for European biotechs have increased, the increase in the US has been higher still, and US investors are increasingly participating and being a driver in larger investment rounds in European companies. The larger and more established funds continue to attract the largest pools for news funds and vehicles and are finding new ways to help their portfolio companies grow. Leading investors discuss the global investment landscape and the part being played by Europe's growth and maturation, as well as what they expect 2022 and onwards to hold.

- Is competition for deals higher than ever?
- Could de-fragmented and re-invigorated European public markets help the maturing ecosystem further and compete with US public markets?
- Evolution of funding vehicles and mandates – early stage, growth, crossovers, SPACs

Moderator: **John Rudy**, Member, Mintz
Sofia Ioannidou, Partner, Andera Partners
Stephanie Sirota, Partner and CBO, RTW Investments
Tej Panesar, Investment Director, Life Sciences, British Patient Capital
John Cassidy, Investment Director Life Sciences & HealthTech, Softbank Vision Fund

PARTNERSHIPS & DEAL MAKING

11:00 The New (And Improved) Normal - Building A More Connected European Ecosystem

After a period of enforced isolation, rather than a breakdown in communication many found efficiencies in the virtual world. As we get back to the 'new normal', how can Europe work to make this an improved normal, with a less fragmented and more collaborative ecosystem? Heads of leading life science hubs building cross-geography partnerships to build an even more robust European ecosystem.

- How are leading life science clusters working to build and develop and ensure success for innovators in their region?
- Cultural, incentive and structural differences across the continent
- Ideas and models for pan-European collaboration

Moderator: **Madeleine Armstrong**, News Editor, Evaluate
Bonnie Van Wilgenburg, Principal, Monograph Capital Partners
Michael Altorfer, CEO, Swiss Biotech Association
Viola Bronsema, CEO, BIO Deutschland
Anette Steenberg, CEO, Medicon Valley Alliance

CAPITAL DEPLOYMENT & COMMERCIALISATION STRATEGY

11:00 The Future Of The Emerging Biopharma Launch Landscape

- Overview of the first-launch landscape - reviewing novel first launches in Europe and the US in the last decade
- Best practices for first launches for COVID and beyond
- Recent trends in launches with a spotlight on cell and gene therapy and oncology
- What can we expect to see in the next 5 years in the emerging biopharma launch landscape?

Ben Hohn, Principal - Pharmaceuticals & Biotech, Emerging Pharma Lead, ZS Associates

Biotech Agenda

11:45 De-Risk Investments And Increase ROI Through Strategic VC CDMO Collaboration

Early stage investment in biotech is high risk due to the low probability of candidate success and increasing competition globally. Lonza has developed a unique business model to partner with VCs, supporting them in de-risking their investments by offering due diligence support and can increase ROI through proven, scalable development and manufacturing solutions for their product supply.

- Partnering with a CDMO which takes a holistic approach to drug substance and drug product development
- How Portfolio companies can simplify their supply chain, resulting in a shortened development timeline
- Minimizing risks and reducing process complexity

Pinna Weitz, Global Head of Venture Capital Business Development & Relationship Management, Lonza

11:45 Presentation: How Automation Is Changing The Way We Think About Labs

Automation has long been a buzzword associated with leading edge science, but is usually resigned to specific assays & methods. However biotech R&D can be transformed by building automation across full laboratory workflows & integrating existing protocols. This session will explore key pillars of automation across laboratory environments to increase throughput, enhance data governance, and improve result comparability. It will also highlight key industries where automation is changing upstream processing for good.

- Integrating existing workflows with automation platforms
- Unlocking comparable results without the hassle
- Baking in automation from the ground up

Nick Pattinson, Head of Product, Automata

11:20 Challenges And Operational Scale Up For First Product Launch

Navigating the 'go-it-alone' strategy is a huge financial, operational, and structural undertaking. However, as the industry grows, evolves and matures, and with more capital in the space than ever before, first launches by emerging biopharma are becoming more commonplace - first launches have made up more than a quarter of all new molecules submitted to the FDA since 2016. Executives discuss...

- What does it take to build, scale and prepare your company for launch?
- Exit valuations after commercialisation compared with a late stage partnering strategy
- Key success factors and considerations in a first launch and evolving into a commercial company

Moderator: **Ben Hohn**, Principal - Pharmaceuticals & Biotech, Emerging Pharma Lead, ZS Associates
Andrew Udell, President, North America, Calliditas Therapeutics
Sally van Kooten, VP Commercial Strategy, KalVista Pharmaceuticals
Francis Pang, VP Global Market Access, Orchard Therapeutics

Biotech Agenda

12:05 Striving For Progress In Diversity & Inclusion

Diversity is strength. Whether gender, ethnicity, or socio-economic background, in an industry that solves complex challenges it is the organisations and companies who have a variety of ideas, experiences, and mindsets that will be the most robust, resilient, and successful. Despite some improvements, there is a long way to go to in a truly equitable environment, and investment in terms of capital to more diverse organisations, but also time and focus is, needed to redress the imbalances. A multi-stakeholder panels discusses how the industry is faring, and what more of it should be doing, in championing Diversity, Equity and Inclusion (DEI).

- The key role of investors leading the way and providing equitable access to funding and resources
- Prioritising DEI - practical steps investors, companies and the industry can take to make a difference
- The importance of collecting data, considering metrics and taking learnings from them

Moderator: **Ian Coyne**, Executive Director Global Information & Intelligence, Coulter Partners
Priya Mande, CEO, PsiOxus Therapeutics
Rhoda Steel, Head of Community Impact, Johnson & Johnson UK

12:05 Moving The Needle - Successful Business Models At The Interface Between Industry, Academia And Investment

The pace of innovation in biotech and life sciences is only increasing and keeping at the cutting edge of new discoveries and next generation technologies is key. Pharma and investors are looking ever earlier to help support these ideas, alongside TTOs and accelerators, to translate early innovation into viable start-ups which can in turn then get treatments and technologies from the lab to the bedside as quickly as possible. A multi-stakeholder panel discusses evolving businesses models, stories of success, and how the whole ecosystem can work more effectively together.

- How to get new technology into commercially viable entities more quickly
- Learning from the successes in the UK ecosystem and how these models can be implemented in other clusters
- What more needs to be done to expedite translation of innovation?

Moderator: **Marc Ramis Castellort**, Venture Partner, Chasing Science
Bill Haynes, Head of Novo Nordisk Research Centre Oxford, Novo Nordisk
Anne Horgan, Partner, Cambridge Innovation Capital
Dima Kuzmin, Managing Director, 4BIO Capital
Jason Mellad, CEO, Start Codon

12:05 Business Models For Cell & Gene Therapy: Evolution Or Revolution From The Existing Biopharma Model?

The advent, development and commercialization of new technologies entails the development and refinement of new business models that allows companies to create, deliver and capture value. Cell and Gene Therapy (CGT) is an exciting frontier in in therapeutics and capital investments are fuelling rapid scientific innovation and providing the opportunity for biotechs to commercialize themselves. However, there are several challenges associated with the CGT business models and some of these vary depending on the therapeutic modality and disease area being targeted. Industry leaders have long been talking about shifting from becoming a supplier of therapeutic products to delivering 'value' in the form of patient outcomes - CGT could be seen as a catalyst and accelerator of this change. But will this change require companies to evolve or create new business models?

- Which components of the biopharma business model are largely impacted by CGT? - value capture, value delivery or value creation
- What does the future of CGT look like?
- How does the system need to evolve for future commercial sustainability?
- What are key capabilities that companies need to invest in to succeed in the future world?

Moderator: **Maya Khurana**, Health and Life Sciences Director, Oliver Wyman
Catherine Isted, CFO, ReNeuron
Jean-Philippe Combal, CEO, Vivet Therapeutics
Lucas de Breed, Founder, August
Elisa Petris, Partner, Syncona

12:45 Lunch Break

Biotech Agenda

13:45 Sourcing And Funding Next Generation Innovation

With more capital available for early-stage companies than ever before, how are investors sourcing the latest innovations with larger rounds, bigger and more diverse syndicates? What are their focus areas and how are they sourcing the latest discoveries and technological advances that will be the next wave of biotech leaders? As focus switches back from pandemic treatments and solutions, panel of early-stage investors discuss the early- landscape and what's exciting them in 2022.

- Will we continue to see investors back the best companies with increasingly larger seed and series A funding rounds to give young companies a stronger runway?
- Geographical syndication – are early-stage investors seeing greater global interest in syndication opportunities?
- In the 'Golden Age of Biotechnology' we are in, which next generation tech is exciting investors?

Moderator: **Chris Rowe**, Innovation Lead, Innovate UK
Edward van Wezel, Managing Partner, BGV
Roel Bulthuis, Managing Director, INKEF Capital
Mehdi Ainouche, Principal, Jeito
Alex Hamilton, Partner, Syncona
Sara Secall, Partner, Inveready

13:45 Making A Mark - Emerging Players In Biotech Deals And Acquisitions

While the world's largest pharma companies often dominate headlines with large 'biobucks' licencing agreements and M&A mega deals, a growing number of smaller pharma companies are also hungry for partnerships, deals and acquisitions. Heads of BD & M&A and emerging deal-makers at growing pharma share their strategies, focus areas and how they are looking to make their mark in the biopharma landscape:

- Finding the right partners and in dedicated ecosystems
- Smaller biopharma's partnering and deal making strategies in a competitive market
- Strategic alignment - key therapeutic areas of interest

Moderator: **Guy Martin**, Deputy Editor, Pharma Letter
Jukka Muhonen, Global BD & Alliances, Orion Pharma
Kieran Rooney, VP, Strategic Alliances and Licensing, Amryt Pharma
Steven Harris, Chairman, CS Pharmaceuticals

13:45 A Platform For Success – Strategic Imperatives In Building And Growing Discovery Platforms

After two decades of venture investors primarily funding product-centric companies, now newly hatched companies with disruptive drug discovery platforms but no identified lead assets are raising historically unprecedented financings. Platform companies face numerous strategic development challenges prior to and beyond the point at which the value of tangible product assets ultimately takes over as the principal valuation driver. The rewards of developing a compelling corporate development strategy can be considerable, since strategically developed platforms are capable of generating enterprise value both more rapidly and expansively than conventional "phase transition" asset development. Early-stage investors and platform company CEOs discuss the strategic imperatives in extracting optimal near and long-term value from discovery platforms.

- Determining and executing near-term preclinical studies
- Selecting and prioritising therapeutic area(s), disease(s) and indication(s)
- Taking a portfolio approach to platform vs target risk
- Developing a proactive strategy to utilize partnering as a strategic value multiplier

Moderator: **Ed Saltzman**, Head, Biotech Strategy, Lumanity
Giuseppe Mazza, CEO, Engitix Therapeutics
Maina Bhaman, Partner, Sofinnova Partners
Arthur Sands, CEO, Nurix Inc.
Klaas Zuideveld, CEO, Versameb

Biotech Agenda

14:30 Preparing For And Protecting Your Assets When Entering The US

Entering the US market can be a challenge, but it is becoming a strategic consideration ever-earlier in the growth process for many companies. Asset protection when entering a new market is the key to long-term success and includes securing capital from investors, preparing for licensing and transactions, and minimizing litigation risk. Efficient and effective due diligence can protect your assets and save you time, money and headaches further down the line. A multi-stakeholder panel will discuss how companies and their investors can optimize their intellectual property portfolios for entry to the US.

- How investors analyse, identify and mitigate risk in investing in life science companies seeking to market in the US
- How to put yourself in the best possible position for investment and deals
- What assets investors and partners will want to see in your intellectual property portfolio
- How to protect privileged and confidential information during the due diligence process

Moderator: **Anita Meiklejohn**, Principal, Fish & Richardson
Tim Luker, VP Venture Science, Corporate BD, Eli Lilly
Pierre-Louis Joffrin, CDO, Mogrify
Robin Bhattacherjee, CEO, Actimed

14:30 Competition Intensifying? China's Partnering And Deal Making Strategies

Records levels of cross-border licensing partnerships have been agreed between multi-national Pharma and Chinese companies through 2020 and 2021. Deals boomed both for Pharma acquiring or partnering on innovative Chinese assets as well as Chinese companies developing and commercialising drugs for Western companies. While capital is still awash in China, this increased activity has meant a more competitive landscape - has sourcing and building win-win deals become ever harder? Executives discuss the booming Chinese partnering and deal-making landscape.

- Will the growth in cross-border transactions with Chinese companies continue?
- In a more global competitive market for deals, how are strategies evolving?
- What are Chinese companies looking for in deals?

Moderator: **Hayley French**, Investor, Vesalius Biocapital Partners
Yuehua Cong, Executive Director, Head of Europe, Simcere Pharmaceutical Group
Maria Dahl, COO and Head of Europe, Innovent Bio
Donald Xu, Managing Director, Lynx Capital

14:30 Panel: Key Multi-Stakeholder Considerations In Early-Stage Commercial Deal-Making

- Are early-stage deals essential to validate pipeline and secure investment? How is raising capital balanced with deal-making?
- What have early-stage partnerships enabled, what hurdles have been faced, and what does it take to make deals work long-term?
- What advice or requests would biotech have for large pharma for early-stage deal-making?
- What advice for successful early-stage deal-making would large pharma give biotech beyond "come back when you have more data"?
- What are strategies for achieving a "fair deal"?

Moderator: **Beth Fordham-Meier**, VP, Business Development, BioConsulting, Lumanity
Khatereh Ahmadi, Head of Search and Evaluation Team, European BD&L Hub, MSD
Steven Powell, CEO, eTheRNA immunotherapies
Anton Mat, Director of Business Development, ISA Pharmaceuticals

15:15 Afternoon Break

Biotech Agenda

16:00 Rebounding, Rebuilding, Reimagined – Pharma Bd & M&A Outlook In 2022 And Beyond

Whilst somewhat dampened through 2020, there are predictions of extensive M&A activity through 2021 and in 2022 as beyond as in-person deal-making returns and the industry rebounds. Both 'mega-mergers' and smaller bolt on deals to supplement pipelines and get cutting edge innovations to patients faster are slated, though with a backdrop of increased scrutiny of larger deals and an increasing diversity in innovation across the healthcare sector. Are Pharma's strategies evolving and can we expect an increasingly active market? Leading global deal-makers discuss how M&A activity will evolve in the biopharma industry.

- With competition authorities increasingly looking at complex M&A activity, what kind of difference could this make to the pharma industry?
- Will smaller bolt-on acquisitions continue as a key engine for driving growth?
- Will oncology continue to dominate deal-making? Which other new technology innovations are the world's largest companies looking at with most interest?

Moderator: **Robbie McLaren**, Partner and Vice Chair of the Global Life Sciences Practice, Latham & Watkins
Matthias Müllenbeck, SVP, Head Global BD & Alliance Management, Merck KGaA
Nigel Sheail, Global Head of M&A and BD&L, Novartis
Brian Heaphy, SVP, Corporate Development, BMS

16:45 Fireside Chat: The Growing Role Of Machine Learning In Rare Disease

A constellation of missed clinical signals contribute to the diagnostic odyssey facing rare disease patients. Patterns in clinical presentation are often misinterpreted, creating a challenging data science problem. Cutting edge predictive machine learning models are generating powerful results – understand how in this fireside chat discussion with Horizon Therapeutics and Komodo Health.

Moderator: **Tina Tan**, Executive Editor, FirstWord HealthTech
Arif Nathoo, Co-Founder and CEO, Komodo Health
Igor Rudychev, VP Enterprise Analytics, Horizon Therapeutics

Biotech Agenda

17:05 Introducing 'Our Future Health'

Our Future Health is an ambitious collaboration between the public, charity and private sectors that will be the UK's largest ever health research programme. The initiative will provide a world-leading resource for health researchers comprising a prospective observational dataset of 5M participants from across the UK combined with a powerful translational research platform. Researchers from around the world will be able to use the resource to discover and test more effective ways to predict, prevent, detect and treat diseases. Backed by more than £100M from life science companies, £79M from Innovate UK and £55M aligned to the Genome UK Strategy, Our Future Health is backed is also endorsed by numerous medical research charities. Key members of the collaboration will provide an overview of Our Future Health, with perspectives from both founding industry and charity members, and will highlight opportunities to get involved and utilise this new and exciting resource.

Moderator: **Anna Williamson (she/her)**, Executive Director, Roche Pharma Partnering
Andrew Roddam (he/him), CEO, Our Future Health
Rebecca Pope (she/her), UK Digital & Data Science Innovation Lead, Roche Products
Wen Hwa Lee (he/him), CEO and Chief Scientist, Action Against AMD
Chris Chamberlain, Executive Director Experimental Medicine, AstraZeneca

17:45 Drinks Reception

18:30 Networking Party @ The Gherkin

Biotech Agenda

Tuesday, 10 May – Satellite Sessions

11:00-12:45



Co-hosted by:



13:45-15:15



Co-hosted by:



16:00-17:45



Co-hosted by:



Wednesday, 11 May – Main Agenda

09:25 LSX Welcome Address

Biotech Agenda

09:30 Go West! – Considerations For US IPOs And Dual Listings

After a record-breaking year in 2020, the IPO market has slowed in 2021. For European companies, what remains is the stark contrast in terms of listings on local European exchanges compared to what is now a well-trodden route to Nasdaq. The huge amount of capital available in the US has long provided a pull for European biotechs and with healthcare in general brought to the fore more than ever before in 2020, many companies took advantage of the open IPO window to list or dual-list in the US. A major consideration for any company, executives who have taken their businesses public in the US discuss the decision and timing their listing, how they managed during in a period of huge disruption and travel restrictions and key success factors in taking European companies to Nasdaq.

- Key considerations for companies looking to tap the US public markets
- What skills and experience are necessary to bring on to your board and management team for life on US public markets?
- The European discount – is the perception of European companies being undervalued (or US companies overvalued) a reality?
- Has the biotech IPO market peaked? Is the window closing?

Isabella Schidrich, Senior Managing Director, Nasdaq
Pierluigi Paracchi, CEO & Co-founder, Genenta Science
Piers Morgan, CFO, Cellcentric
Fredrik Johansson, CFO, Calliditas Therapeutics

10:30 Morning Break

CAPITAL MARKETS & INVESTMENT

PARTNERSHIPS & DEAL MAKING

CAPITAL DEPLOYMENT & COMMERCIALISATION STRATEGY

Biotech Agenda

11:00 Fireside chat: SPACS – Are They Here To Stay And How Will They Evolve?

Whilst blank cheques are not a new vehicle, SPACs in biotech and healthcare have exploded and been the hottest trend in the sector. There is much debate around the pros and cons, with SPACs allowing the ability to merge crossover rounds with the IPO into one step and giving speed to market for the companies, but many, including at Pharma, have reservations. Are SPACs here to stay in the life science industry for the long term? Experts and SPAC sponsors discuss the recent boom, the future of the vehicles in the space and how the products could evolve moving forward

- What are the pros and cons for companies considering a SPAC compared to a traditional IPO?
- What makes a company attractive for a de-SPAC merger?
- Are these vehicles, which have exploded in the US, to become increasingly commonplace in Europe?

Moderator: **Jim Polson**, Managing Director, FTI Consulting
Jasper Bos, General Partner, Forbion; CEO, Forbion European Acquisition

11:00 Go-To-Market Strategies Across Geographies And Overall Equity Returns

Biotech companies' commercial planning should be starting earlier and earlier as industry dynamics shift. A key consideration will be the strategy around commercialising in different geographies and potential partnerships in licencing or co-promotion. But how do these decisions affect overall equity returns? After a presentation of in-depth analysis to date, executives and investors discuss:

- Developing a global commercial strategy and considerations for commercialisation rights
- Going alone or licencing or co-promoting across different geographies and how that impacts overall equity value
- Analysing the importance of retention of commercialisation rights in different geographies
- Investor perspectives on biotech's commercial strategies

Presenter and moderator: **Cody Powers**, Principal - Portfolio & Pipeline, ZS Associates
Peter Llewellyn-Davies, CEO, invIOs
Erik van den Berg, CEO, AM Pharma
Renee Aguiar-Lucander, CEO, Calliditas Therapeutics
Regina Hodits, Managing Partner, Wellington Partners

11:00 Managing Risk In The New World – Security, Data, Resilience In The Biopharma Supply Chain

The last 24 months have been quite historic for organisations within the life sciences and healthcare industries. In addition to the obvious global COVID-19 response, businesses have continued to grow and evolve in cyber terms. Whether it be innovations in cyber-enabled treatments or therapies, or making the best use of technology to support efficient delivery of organisational objectives and business strategies, one thing is clear – the industry is at the very forefront of the cyber operating environment. With this level of innovation, the heightened degree of interaction within the cyber space, and in considering the 'data heavy' and highly regulated nature of the industry, all against a backdrop of growing and emerging cyber threats, it is crucial that life science and healthcare organisations of all types view cyber risk as being amongst, if not the, biggest risks to their businesses.

- What does the cyber threat landscape look like for this industry?
- Have cyber security practices kept pace with innovation and the implementation of new technologies?
- Is the convergence of the physical and virtual domains fully understood by this industry, and what are the risks in this space?
- How can organisations better protect themselves in the now, and what or where should they focus their efforts in looking ahead?

Moderator: **Andrew Hill**, Product Innovation Lead, WTW
David Crome, Managing Director Compliance UK, ProPharma Group
Simon Basham, Head of Cyber & TMT Broking UK, WTW

Biotech Agenda

11:20 What's Next Now The Music Has Stopped? - Assessing The Volatile Public Markets

The pandemic-caused global recession passed biotech by in 2020 and 2021, with investment and funding reaching record levels including an explosion of IPOs, SPACs and follow-ons. 2022 so far has been a different story with the S&P index of biotech stocks down significantly alongside more macro issues of economic recovery from the pandemic and major macro-economic and geopolitical uncertainties. The question now becomes, what next for the public markets and is the current environment sustainable? Fund managers and analysts debate the future of the capital markets.

- Was biotech due this correction and to this extent?
- The impact and risks of the deep-pocketed new entrants to healthcare investment and their long-term stickability
- What are the reasons for optimism, and what are the ongoing risks and challenges?
- What could the future look like for the next generation of drug developers?

Moderator: **Lala Gregorek**, Healthcare Analyst, Trinity Delta
Ulrica Slåne Bjerke, CIO, Arctic Aurora LifeScience
Tara Raveendran, Head of Healthcare & Life Sciences Research, Polar Capital
Victoria Darbyshire, Equity Analyst, J.P. Morgan

11:40 Dressing For Success Early As A Biopharma Startup

Pre-Clinical biopharma start-ups often don't have time to rest – always needing to propel their organization to their next phase of development. But what that next phase of development looks like uniquely to that organization is often unclear and when do they need to 'dress' for it are common questions. Identifying the structural, technical, and development challenges to plan for in trying to get to the next level are widely complex. In this panel, hear from newly formed companies and how they worked through their planning process and set themselves up for their next phase of growth, issues they faced along the way, and the realities they face as a start-up.

Moderator: **Matt Cardinal**, VP Strategy & Program Leadership, Halloran
Ros Deegan, CEO, OMass Therapeutics
Valerie Vanhooren, CEO & Co-Founder, ONA Therapeutics
João Siffert, CEO & President, Design Therapeutics
Suzanne Dilly, CEO, ValiRx

Biotech Agenda

12:00 Presentation: Successful Partnerships When Outsourcing – Key Considerations And Delivering Business Value

Selecting the right outsourcing partners is critical to growing biotechs, and no area more so than with laboratory services. This session will highlight some of the key considerations when selecting an outsource partner as well as the potential business value that can be gained through effective partnerships

- Regulatory acceptance
- Depth v Breadth of service and Experience v Expertise
- Global or local?
- 3rd party co-operation

Jette Cowan, Head Of Commercial – Pharmaceuticals, RSSL

Biotech Agenda

12:20 Finding The Fit - Win-Win Deals In Pharma Partnering

As the pace of innovation across the healthcare space increases, pharma are ever-more active in scouting for early and later stage deals. The expertise, resources and connections of industry giants remains critical, but in a sector awash with capital and with increased competition, are strategies changing? Pharma S&E and BD executives discuss how they are supporting innovation, going earlier in building their pipelines, and the increasingly competitive landscape for attractive deals.

- “Earlier and earlier” cried Alice in Pharmaland - how are the industry biggest players looking to source innovation sooner and support the youngest startups?
- Is it more competitive than ever before?
- What are the key considerations for companies in their partnering strategy approaching pharma, and are most commonly overlooked?
- Which type of partnering at which stage?

Moderator: **Stephanie Léouzon**, Partner, Torreya
Tim Luker, VP Venture Science, Corporate BD, Eli Lilly
Marta Helena Lesko, Head of BD Enabling Technologies, Merck KGaA
Markus Kalousek, Global Head Search & Evaluation, Novartis
Tahera Kan, VP Transactions, Johnson & Johnson Innovation EMEA, Johnson & Johnson

12:20 Multi-Jurisdictional Drug Development

The pandemic had ripple effects throughout the healthcare industry, one of which being regulatory healthcare authorities undergoing their own adaptation and changes. A lot more communication between regulators in different geographies is now more common, with a lot more sharing of information. Experts and companies who are undertaking and multi-jurisdictional drug development discuss what this means for companies and the wider industry post-covid.

- Navigating drug development strategy across the FDA, EMA, MHRA and other regulatory bodies
- Key success factors in targeting multiple jurisdictions at the same time
- Starting early and with the end in mind whilst avoiding common pitfalls and bottlenecks

Moderator: **Johan Strömquist**, CEO, NDA Group
Björn Carlsson, Principal Consultant & Advisory Board Member, NDA Group
Nicklas Westerholm, CEO, Egetis Therapeutics
Tim Morris, COO/CFO, Humanigen

13:00 Lunch Break

Biotech Agenda

14:00 Fireside Chat: Realising Opportunities And Potential In Cell Therapy

- *Novo Nordisk's work in cell therapy and therapeutic areas being expanding into*
- *Manufacturing capabilities have and US manufacturing expansion - considerations of build vs buy*
- *Ambitions within cell therapy in the coming years*

Moderator: **Franc Gregori**, Analyst, Trinity Delta
Sofia Håkansson Buch, VP Cell Therapy CMC, Novo Nordisk

14:20 Shaping The Future Of Advanced Therapies - Time To Deliver And Realise Full Value?

The promise and hype of advanced therapies is finally translating into a reality and represents the next major wave of therapeutics. With mRNA vaccines playing a lead role in the fight against COVID-19 providing further optimism and validation, Pharma and biotech have burgeoning pre-clinical and clinical pipelines across various therapeutic areas - over 60 C> products have been approved worldwide and there are around 2,000 open or planned clinical trials. With huge increases in investment and M&A activity is in the space, the future of cell and gene therapies is bright, but many challenges remain - what is the future of advanced therapies, and how are companies working to expedite getting this technology from bench to bedside?

- *While oncology still dominates, which other therapeutic areas are showing promise?*
- *Clinical challenges - limited sites performing perform C> trials effectively, patient recruitment and long-term follow-up*
- *Manufacturing challenges - time, labour intensive and expensive processes, supply chain risks, achieving commercial scale*
- *Reimbursement and commercialisation challenges - high costs and proving value, obtaining reimbursement across geographies, public misinformation*

Moderator: **Lala Gregorek**, Healthcare Analyst, Trinity Delta
John Dawson, Director, Oxford BioMedica
Sven Kili, CEO, Antion
Jason Foster, CEO, Ori Biotech
Sofia Håkansson Buch, VP Cell Therapy CMC, Novo Nordisk
Marcel Zwaal, CEO, Gadeta

Biotech Agenda

15:10 Making The Undruggable, Druggable - The Exciting Potential Of Targeted Protein Degradation

The concept of targeted protein degradation presents revolutionary drug development opportunities and, similar to technology innovations which have come before like gene-editing, is anticipated to bring about a paradigm shift in modern healthcare in the coming years. As the TPD field grows, with increased investment and more Pharma programmes, new companies emerging with new approaches and assets entering the clinic, executives discuss this new frontier of medicine, and what is needed to realise its full potential.

- *What are the limitations of existing TPD approaches, and what could the next generation look like?*
- *Do TPD drugs have the potential to be the next blockbusters?*
- *What are the key challenges in the TPD field? Which key factors that are likely to influence the evolution the area?*

Moderator: **Lisa Melton**, Senior News Editor, Nature Biotechnology
Tom Shepherd, CEO, Captor Therapeutics
Christian Dillon, CSO, Phoremest
Bernd Boidol, CEO, Proxygen
Nicki Thompson, CEO, Amphista Therapeutics

16:00 Close Of Congress

Biotech Agenda

Wednesday, 11 May – Satellite Sessions

11:00-12:30 Applying Recent RWE Guidance to Your Development Program



Led by:

Nach Dave, Vice President Development Strategy, Premier Research
Abie Ekangaki, Vice President, Statistical Consulting, Premier Research
Angela Drew, Director Regulatory Strategy, Premier Consulting

Co-hosted by:



14:00-15:30 Real-World Complexities in Development-Stage M&A Transactions



Development-stage M&A transactions often include substantive milestone and other post-closing payment structures. Lawyers from pre-eminent life sciences firm Covington & Burling will lead a discussion considering the complexities of deferred consideration payment terms in development-stage M&A transactions, drawing on their experience and multidisciplinary approach.

The session will explore the key legal and commercial issues at stake when negotiating deferred consideration payments.

Led by:

James Halstead, Partner, Covington & Burling
Sarah Cowlshaw, Partner, Covington & Burling
Guy Dingley, Partner, Covington & Burling
Morag Peberdy, Of Counsel, Covington & Burling

Co-hosted by:

COVINGTON

Healthtech Leaders



HEALTHTECH LEADERS

Life Science & Digital Health Partnerships

Capital Markets & Investment

Payers, Providers & Reimbursement

Healthtech Speakers



Richard Cassidy
SVP Rx+ Business
Accelerator, Astellas
Pharma



Mark Davies
Chief Medical Officer,
IBM



**Caoimhe Vallely-
Gilroy**
Global Head of
Digital Health &
Therapeutics, Merck




Chris Robson
CEO, Living With



Hanno Ronte
Partner, Monitor
Deloitte



Derk Arts
CEO, Castor



Jessica McCreadie
Principal, Octopus
Ventures



Mark Slaughter
SVP Business
Development,
Sidekick Health



Jacob West
Director, Healthcare
& Life Sciences,
Microsoft



Tina Tan
Executive Editor,
FirstWord HealthTech



David Atkins
CEO, Congenica



Neil Ward
VP EMEA, Pacific
Biosciences




Ali Hasan
Chief Medical &
Healthcare Officer,
Vitality Health



Tobias Silberzahn
Partner, McKinsey



Cyndi Williams
CEO, Quin



Michael Niddam
Co-Founder &
Managing Director,
Kamet Ventures



Rana Lonnen
Managing Director,
dRx Capital, Novartis



Valerie Hepp
Digital and PHC
Partnering Europe,
Roche




Megan Coder
Vice President of
Global Policy, Digital
Therapeutics Alliance



Mark Davies
SVP of Informatics
and Data,
BenevolentAI



Steve Carney
Editor, Drug
Discovery Today



Neil Sahota
United Nations
Artificial Intelligence
Advisor & Interim
CEO, ACSILabs



Robert Garber
Partner,
7WireVentures



Susan Thomas
Clinical Director,
Google Health UK

Healthtech Speakers



Zach Henderson
Chief Commercial
Officer, Glooko



Dan Vahdat
CEO, Huma



Christian Hein
VP Global Head DT &
IE, Novartis



Mats Berggren
Head of S&E, Digital
Innovation & External
R&D, Merck



Assaf Barnea
CEO, Sanara Ventures




**Martin-Immanuel
Bittner**
CEO, Arctoris



Jan Kimpen
Chief Medical Officer,
Philips




Rajiv Tanna
Co-founder & CPO,
Birdie



Steve Tolle
Partner, HLM
Ventures



Rachel Ford Hutman
Founder and CEO,
Ford Hutman Media




Josep Sanfeliu
Managing Partner,
Asabys



Eyal Zimlichman
Chief Innovation
and Transformation
Officer, Sheba
Medical Center



Parker Moss
Chief Commercial
Officer, Genomics
England



**Ethan Wergelis-
Isaacson**
Digital Health
Strategy, Otsuka



David Norton
Lead Innovation
Consultant, Royal
Free London
Foundation Trust




**Annemijn
Eschauzier**
Mentor; former CMO
Women's Health, GE




Tony Proctor
Partner, Potter
Clarkson




Neil Gomes
System SVP, Digital
Human Experiences,
Common Spirit
Health



Mike Alavarez
CEO, Qardio




Paul Landau
CEO, Careology



**Caroline
Noublanche**
CEO, Apricity



Nazar Rasul
VP Global Head of
Digital, Fresenius
Kabi



Arif Nathoo
CEO, Komodo Health



Djork-Arne Clevert
Director Machine
Learning, Bayer

Healthtech Speakers



Sarah Yusuf
Group Director,
Sandwell & West
Birmingham NHS
Trust



Gregoire Guillet
Chief Business
& Value Officer –
WeHealth Digital
Medicine, Servier



Marta Gaia Zanchi
Founder and
Managing Partner,
Nina Capital



Matt Fujisawa
Global Head
of Corporate
Development, KRY



Bleddyn Rees
Chair, The Digital
Health Society; Board
Director, ECHAlliance



Alexander Chekan
Chief of Staff, Palta



**Fabian
Scheugenpflug**
Ventures, Startup
Creosphere powered
by Plug and Play



**Sokratis
Papafloratos**
CEO, Numan



**Jonathan
Edgeworth**
Consultant
Microbiologist and
Infectious Disease
Clinician, Guys and
St Thomas NHS
Foundation Trust

Healthtech Agenda

Tuesday, 10 May – Main Agenda

09:00 LSX Welcome Address

09:10 The Evolution Of Healthcare & The Role Of Digital In The Transition To A Value Based Approach

With pressure on global health systems, providers and staff increased to unsustainable levels, the COVID-19 pandemic has highlighted the need for radical change in healthcare, but also how much can be achieved in a time of crisis. Looking forward, a totally different approach to care organization, delivery and distribution will be needed to help deliver better outcomes, improved patient and staff experience and lower cost of care. This keynote session explores the need more than ever to step up collaboration, information and knowledge sharing, and agility in the delivery of diagnostic and monitoring systems at scale. How we can utilise the technology that can collect, qualify, and analyze data in ways that quickly reveal patterns and hidden insights and examine the ways in which the pandemic has spurred the move to virtual care and how remote patient management can provide valuable relief to healthcare systems.

Jan Kimpen, Chief Medical Officer, Philips

09:40 The Fight For Healthtech Investment Opportunities Post Pandemic – Are The Tables Turning For Investors?

Evolution in the healthcare market and the way care is delivered has changed dramatically over the past 12 months, with the way the entire populations have been receiving healthcare flipping to a predominantly technology focused approach and the amount of money being invested within healthtech reaching new heights. This is leading to a lot of companies getting access to large amounts of money and can commercially scale faster, however where once companies had to fight to get investors over the line, investors are now fighting to compete for the best companies in a company driven market. A panel of experts discuss

- What impact has Covid-19 had on healthtech and digital health investment?
- How do digital health companies typically demonstrate value?
- Which value pools are investors most excited about?
- Traditional investors vs new investors in this space

Moderator: **Rachel Ford Hutman**, Founder and CEO, Ford Hutman Media
Steve Tolle, General Partner, HLM Venture Partners
Assaf Barnea, CEO, Sanara Ventures
Michael Niddam, Co-Founder & Managing Director, Kamet Ventures
Rana Lonnen, Managing Director, dRx Capital, Novartis
Christoph Kausch, Managing Partner, MTIP

Healthtech Agenda

10:30 Morning Break

11:00 Measuring Digital Transformation Progress & Assessing The Key Opportunities Ahead

The life sciences industry is at an inflection point. While life sciences companies understand that the digitally enabled organization is the future of health, many approached digital transformation pre-COVID-19 in a more targeted and incremental way that lacked a holistic business transformation lens. In an increasingly digital, patient-experience, and insight-driven health care world, an uncoordinated approach to digital transformation simply won't work any longer. Hear insights on how life sciences executives are making focused digital technology investments that are coming together to change the status quo and transform activities across functional areas and value streams. Hear how such leapfrog digital innovation could bring transformative benefits, including realizing ambitious goals earlier, engaging patients and partners optimally, and bringing drugs to market faster.

Hanno Ronte, Partner, Monitor Deloitte

11:20 Pharma's Transformation Through Digital Innovation - The Merging Of Healthcare & Technology As A 'Full Stack' Opportunity

It is no secret that digital transformation in the pharmaceutical industry is crucial for improved patient care, cost-effectiveness, greater transparency, improved production and drug development. Add to that the acceleration of adoption of various digital technologies in order to overcome the challenges caused by the pandemic and there has never been a more pivotal time within pharma and healthcare. A panel of pharma leaders discuss the changes they are implementing and what the vision for 'after' Covid entails

- How has the pandemic changed the perception of digital and shifted towards a more innovatively focused approach?
- Cross industry collaboration and what this looks like in reality
- Digital as a tool to create better experiences for patients and physicians
- Acceleration of clinical development through multiple investable and scalable solutions
- The importance of data modelling, platforms and science in the development of healthcare solutions and services

Moderator: **Hanno Ronte**, Partner, Monitor Deloitte

Nazar Rasul, Global Head of Digital, Fresenius Kabi

Gregoire Guillet, Chief Business & Value Officer - WeHealth Digital Medicine, Servier

Richard Cassidy, SVP Rx+ Business Accelerator, Astellas Pharma

Christian Hein, VP Global Head of Digital Transformation & Innovation Execution, Novartis

Healthtech Agenda

12:05 Big Tech, Big Ideas: How Are The World's Biggest Tech Companies Addressing Healthtech's Biggest Challenges

A panel of big tech players, both established, new entrants and those looking to scale back their offering within the healthcare space, debate and discuss their respective strategies regarding the industry, focussing on enabling patients, improving clinical, operational effectiveness and personalised care and what's next for healthcare?

- What are the differing strategies of tech giants and where do they see their roles in the fast-moving world of digital healthcare?
- Mega-alliances and collaborative ecosystems; how are tech leaders building the future of healthcare?
- In what ways are big tech leveraging and adapting their core business strengths for healthcare application

Moderator: **Rachel Ford Hutman**, Founder and CEO, Ford Hutman Media

Mark Davies, Chief Medical Officer, IBM

Susan Thomas, Clinical Director, Google Health UK

Jacob West, Director, Healthcare & Life Sciences, Microsoft

12:45 Lunch Break

13:45 In The Digital Therapeutics Race What Is The Best Route To Success?

Digital therapeutics have been gaining traction for years, but the digital health field's explosive growth during Covid-19 pandemic is helping these companies carve out a space in the market for their products. Federal regulators loosened some requirements to make digital health tools more accessible and DTx companies saw an opportunity to prove their worth, however the sector still face challenges that could slow its widespread adoption. A panel of DTx advocates discuss the challenges this growing sector face and how they are overcoming them

- Clinician and patient engagement and trust regarding digital health tools in healthcare
- Real world data and evidence to evaluate and measure value
- Route to market and categorising DTx within healthcare ecosystems
- Perspectives on pharma-DTx partnerships

Moderator: **Megan Coder**, Vice President of Global Policy, Digital Therapeutics Alliance

Caomhe Valley-Gilroy, Global Head of Digital Health & Therapeutics, Merck

Chris Robson, CEO, Living With

Zach Henderson, Chief Commercial Officer, Glooko

Robert Garber, Partner, 7WireVentures

Healthtech Agenda

14:25 Presentation: Key Learnings From The World Health Organization (WHO) Covid-19 Solidarity Trial – The World’s Largest Adaptive Trial

The COVID-19 pandemic transformed nearly every aspect of everyday life. To combat the largest pandemic in recent history, the World Health Organization (WHO) needed to mount a massive clinical trial, while addressing varying challenges and complexity of bringing together thousands of investigators and sites in over 30 countries. In this presentation, learn how to leverage emerging technology and incorporate these same practices in your clinical development and DCT strategy.

Derk Arts, CEO, Castor

14:45 Key Success Factors In Healthtech Fundraising

A panel of healthtech companies discuss the key success factors for raising early-stage capital, identifying the key pitfalls of the current fundraising environment and debating how, in an increasingly competitive sector, healthtechs with potentially unproven products can distinguish their product and demonstrate concrete outcomes.

- Demonstrating USPs and proving use cases - differentiating yourselves from competition
- Gaining traction with investors - how much and what data and business models do investors need to see?
- Ensuring protection of your innovation and proving commercial strategy

Moderator: **Tony Proctor**, Partner, Potter Clarkson

Alexander Chekan, Chief of Staff, Palta

Fabian Scheugenpflug, Senior Ventures Associate, Startup Creasphere powered by Plug and Play

Sokratis Papafloratos, CEO, Numan

15:30 Afternoon Break

16:00 The Rise And Growth In The Market, What Is Next For Women’s Healthtech - A 360 Degree Perspective Of Investment, Partnering & Deal Making

The global women’s healthtech market is already valued at \$1.5 billion in 2020 and is expected to have a CAGR of 20% this decade. With investment pouring into the market and a spotlight shone from healthcare commercial leaders looking for deals and partnerships, it’s an exciting time for an underserved industry. What are the drivers behind the rise of the industry and what shape will this growth take? A multi-stakeholder panel from across the women’s health technology industry discuss the drivers in the market, their vision for the future convergence in combining technologies, and most importantly – what’s next?

Moderator: **Annemijn Eschauzier**, Mentor; former CMO Women’s Health, GE

Jessica McCreadie, Principal, Octopus Ventures

Caroline Noublanche, CEO, Apricity

Caoimhe Vallely-Gilroy, Global Head of Digital Health & Therapeutics, Merck

Healthtech Agenda

16:45 How Genomics Is Revolutionising Healthcare & What Does The Future Hold?

By 2025 the size of the global genomics market is predicted to reach £24B, with next generation sequencing revolutionising the industry and genomics technology having changed dramatically over the last few years - the possibilities created by improved knowledge of the human genome are almost limitless. The genomics industry is hugely diverse, ranging from companies using genomic data to identify new drug targets to those developing technologies for sequencing genomes more quickly, cheaply and accurately than ever before. A panel of genomic innovators and stakeholders explain the ever-increasing potential of genomics in healthcare and life sciences, and the challenges which the ecosystem must still overcome in order to capitalise on this growing market.

Moderator: **Neil Ward**, VP EMEA, Pacific Biosciences

David Atkins, CEO, Congenica

Parker Moss, Chief Commercial Officer, Genomics England

Jonathan Edgeworth, Consultant Microbiologist and Infectious Disease Clinician, Guys and St Thomas NHS Foundation Trust

17:30 Drinks Reception

18:30 Networking Party @ The Gherkin

Wednesday, 11 May – Main Agenda

09:00 LSX Welcome Address

Healthtech Agenda

09:15 The Powerhouse Of Digital Transformation – How We Can Prevent The Next Epidemic Or Pandemic Through Ai & Convergence

As we've seen with COVID-19, viruses can be major slayers to public health and the world's economy. There's real concern about what the next big virus might be, the mutations of COVID-19 into seasonal diseases, and/or viruses teaming up to take down people. Thankfully, there is hope! Taking a page from manufacturing, we can combine artificial intelligence (AI) and generative design to identify millions of potential virus outbreaks. Armed with this knowledge (and virus genomics), researchers could pinpoint preventive measures, or perhaps even a vaccine before the viral outbreak...and allow us to stop an epidemic, let alone a pandemic, before it even occurs.

Neil Sahota, Artificial Intelligence Advisor, United Nations; Interim CEO ACSILabs

09:45 Advancing The Role Of Real-World Data To Support The Development Of The Healthtech Landscape & The Future Of Medicine

The digitalisation of medical records has created access to reams of data about patient outcomes, but with so much information, not all of it has found a use. Real world evidence in and of itself is just that, data; it is the insights garnered and the questions answered because of it that really make this data invaluable. A panel of experts discuss the increasingly important role that real world data is playing within healthtech and what possibilities the future holds for this vital resource.

- How important is it to increase and improve communication on the benefits of generation and use of RWD?
- How is the industry most innovatively leveraging RWD for clinical and observational research?
- How can use of RWD most effectively drive effective outcomes?

Moderator: **Bleddyn Rees**, Chair, The Digital Health Society; Board Director, ECHAlliance

Ali Hasan, Chief Medical & Healthcare Officer, Vitality Health

Dan Vahdat, CEO, Huma

Arif Nathoo, CEO, Komodo Health

Mike Alavarez, CEO, Qardio

10:30 Morning Break

Healthtech Agenda

11:00 Digital Healthtech Business-Building & The Emergence Of Digital Health Ecosystems

- Building, scaling and business building strategies for digital health tech companies
- Introduction of digital health ecosystems and case studies of emerging digital health ecosystems
- Opportunities for healthcare companies around partnering with digital health ecosystems

Presenter and moderator: **Tobias Silberzahn**, Partner, McKinsey

Mark Slaughter, SVP Business Development at Sidekick Health

Dan Vahdat, CEO, Huma

Matt Fujisawa, Global Head of Corporate Development, KRY

11:40 Creating Meaningful Partnerships In Pharma: A Deep Dive Into What Healthcare's Commercial Leaders Are Looking For When It Comes To Innovation, Acquisitions & Partnerships

As health systems find themselves increasingly under pressure, pharma has a unique opportunity to broaden the basis of their engagement with healthcare systems and can look to build trusted partnerships around a common purpose of supporting the delivery of better patient outcomes, data driven insights to improve treatment and care pathways to optimise the use of healthcare resources. A panel of commercial leaders at the forefront of this drive for innovation discuss their aims and vision for the year ahead

- Re-defining the relationship between pharma and healthcare systems
- Requirements for successful trusted partnerships
- Partnership models: From transactional to relationship building
- The rise of DTx & Pharma

Moderator: **Josep Sanfeliu**, Managing Partner, Asabys

Mats Berggren, Head of Search & Evaluation, Digital Innovation and External R&D, Merck

Ethan Wergelis-Isaacson, Digital Health Strategy, Otsuka

Valerie Hepp, Digital and PHC Partnering Europe, Roche

Healthtech Agenda

12:20 The Digitalisation Of Hospitalisation – How The Hospitals Of Today Are Looking To The Technology Of Tomorrow, To Provide A Patient First Vision Of Healthcare From Admission To Discharge

Digitalisation is causing upheaval across society and throughout the globe, from videoconferencing disrupting traditional ways of working to the boom of ecommerce overtaking high street shops. This digital disruption has gone right to the heart of healthcare and hospitals as well, with health systems having to now focus on meeting the expectations of increasingly sophisticated consumers. The impact of this disruption will last beyond the pandemic and digitalising healthcare institutions will be a mammoth task – but the past 18 months have shaken this sector causing them to regroup, adapt and plot a path to the future. A group of experts discuss their vision for the hospitals of the future and the road they are taking to get there

- Coordination and interoperability as a barrier to digital transformation, driving efficiencies and streamlining patient care
- Cyber security: Building a robust digital foundation to guard against data loss and adoption of connected devices
- Innovation and intelligent automation: Bringing efficiency benefits, intelligent automation of business processes and core clinical processes

Moderator: **Sarah Yusuf**, Consultant Radiologists & Group Director, Sandwell and West Birmingham NHS Trust
Eyal Zimlichman, Chief Innovation and Transformation Officer, Sheba Medical Center
David Norton, Senior Lead Innovation Consultant, Royal Free London Foundation Trust
Neil Gomes, System SVP for Digital & Human Experiences, Common Spirit Health

13:00 Lunch Break

14:00 How AI, Machine Learning & Big Data Are Disrupting The Drug Discovery & Development Landscape For Faster And More Accurate Lead Identification

Drug discovery is ripe for disruption. A time consuming and expensive process, taking years and costing billions, the industry is crying out for faster and more accurate drug targets to test at clinical trials. However technology has not been able to keep up, until now. A panel of leaders discuss the future possibilities and applications

- The role in cost cutting of new drug spend and development times
- AI collaboration to target, identify and diagnose faster
- Gaining insights from clinical trial data

Moderator: **Steve Carney**, Editor, Drug Discovery Today
Martin-Immanuel Bittner, CEO, Arctaris
Neil Sahota, Artificial Intelligence Advisor, United Nations; Interim CEO ACSILabs
Djork-Arne Clevert, Director Machine Learning, Bayer
Marta Gaia Zanchi, Founder and Managing Partner, Nina Capital
Mark Davies, SVP of Informatics and Data, BenevolentAI

Healthtech Agenda

14:45 A Spotlight On The Brightest Next Generation Of Healthtech Startups

Amidst the pandemic crisis, the healthcare and life science industries have come under increased scrutiny, be it global, national or private healthcare providers. However, healthtech has never been so top-of-mind as companies scaled up to meet pandemic demand. 2020 saw record highs of investment within European healthtech, jumping up by \$750m from the previous year and some hefty funding rounds with many telemedicine and digital diagnostic startups seeing huge jumps in user numbers. With the focus firmly on healthtech for the foreseeable future and the global healthtech industry currently worth a staggering \$8tn, a panel of the latest and greatest startups discuss their ambition and vision for growth in this competitive landscape

Moderator: **Tina Tan**, Executive Editor, FirstWord HealthTech
Rajiv Tanna, Co-founder & CPO, Birdie
Cyndi Williams, CEO, Quin
Paul Landau, CEO, Careology
Caroline Noublanche, CEO, Apricity

15:30 Close Of Congress

Medtech Leaders



MEDTECH LEADERS

Design, Development & Digitalisation

Capital Markets & Investment

Market Access & Commercialisation Strategy

Medtech Speakers



Wilfred Van Zuilen
President EMEA,
Zimmer Biomet



Charity Kufaa
VP BD and Strategy,
Medtronic



Xavier Bertrand
VP Healthcare
Services and
Alliances, Boston
Scientific



Antonio Sanchez-Cordero
VP BD (M&A)
Peripheral
Intervention, BD



Rupert Winckler
Head of BD EMEA,
Olympus



Thomas Hummel
Digital
Transformation Corp
Dev, Fresenius Kabi



Markus Ott
VP and Head of
Global Market Access
and Health Policy,
Roche Diagnostics



Stephen Reese
Partner, Clifford
Chance



Antoine Pau
Senior Partner, Truffle
Capital



Josh Valman
CEO, RPD
International



Georg Bortlein
Founder & President,
High Life



Zina Fragkiadaki
Senior Reporter,
HealthInvestor UK



Oliver Keown
Managing Director,
Intuitive Ventures



Mike Harris
CEO, Biocomposites




Susanne Schorsch
Vice President
Business
Development,
Comphyra



Marc Julien
Co-CEO, Diabeloop



Laurent Vandebrouck
CEO, Chronolife



Eliane Schutte
CEO, Xeltis



Ian Crosbie
CEO, Sequana
Medical



Tim Mitchell
VP Strategic
Programs, NAMSA



Juliette Cook
Vice President
Quality & Regulatory
Affairs, Implantica



John Lee Allen
Managing Partner,
RYSE Asset
Management



Carina Tyrell
Chief of Staff &
Investment Associate,
Walden Catalyst
Ventures



Frank Maddux
Global Chief Medical
Officer, Fresenius
Medical Care

Medtech Speakers



Baudouin Hue
Partner, Karista



Brittanie Campbell
Account Executive,
Greenlight Guru




Jérôme Stevens
General Manager &
co-founder, Webhelp
Medica



Bruce Lichorowic
President & CEO,
Galen Robotics



Laura Niklason
CEO, Humacyte



Jonathan Wood
Regional Director,
Abbott Vascular



Per Vegard
CEO, CMR Surgical



Seamus Browne
Head of Industry
Partnerships, Royal
College of Surgeons
in Ireland



Jose Calle Gordo
Operating Partner,
Valiance



Peter Finnie
Partner, Potter
Clarkson



Carl Hewett
Head of Medical
Design Innovation,
Sagentia Innovation



Brian Hakim
Director Business
Development,
MedTecX




Linda Korthout
Director International
Clinical Affairs, MCRA



Sergio Levi
Vice President
Strategic Alliances,
Philips



John Milad
CEO, Quanta Dialysis
Technologies



Laurie Rowe
Director & Founder,
RED Medtech



Gunnar Sachs
Partner, Clifford
Chance




Ari Silverman
Partner, Mavie
Technologies




Angela Liedler
Managing Director,
Precisis




Robert Kieval
EVP Strategic
Partnerships, Veranex



Claire Woodthorpe
VP, Europe & COO,
Lightpoint Medical



Gil Rabbie
Digital Solutions
& Capability
Development Leader,
Boston Scientific



Diana Saraceni
Managing Partner,
Panakès Partners



Drew Burdon
Partner
EQT Life Sciences

Medtech Speakers




Lord David Prior
Former Chair, NHS
England; Global
Senior Advisor, Lazard



Luke Hares
CTO, CMR Surgical



Peter Bowness
Former Senior
Regulator, BSI




Gadi Toren
Investment Partner,
Robert Bosch
Venture Capital



Elizabeth Cairns
Medtech Reporter,
Vantage



Ariana Adjani
Co-Founder, Fine
Treatment



Hamman de Vaal
Chief Commercial
Officer, AdjuCor

Medtech Agenda

Tuesday, 10 May – Main Agenda

09:00 LSX Welcome Address

09:10 Next Steps For Medtech: Convergence & Collaboration

- How the NHS is approaching and managing convergence of technologies for health and care
- Working to deliver better patient outcomes during a period of huge disruption and stress on the system
- The role medical devices and health technologies are playing and how this is evolving
- How the NHS is collaborating with the industry in different ways - partnerships, infrastructure, working with different existing and new 'players' in health and care
- What more needs to be done?

Lord David Prior, Former Chair, NHS England; Global Senior Advisor, Lazard; Chair, Cambridge Life Sciences Council

09:30 Keynote Opening Panel: Medtech's Post-COVID-19 Transformation And Growth Strategy

In a post-Covid environment, healthcare systems are dealing with a significant challenges and backlogs across all specialities. At the same time, medtech companies are offering technology and data that can help to overcome these backlogs and other pressures on healthcare systems, as they partner closely with healthcare providers both public and private. A panel of leaders from big medtech discuss the state of what is an exciting but challenging medtech market and the industry's return to growth.

- What is the global medtech outlook post-COVID – challenges and opportunities?
- How are pre-, intra- and post-operative technologies helping providers and health systems manage backlogs in treatment and surgery?
- How are medtech's biggest players working to more effectively partner with hospitals and healthcare networks and system?
- Developments and strategies in medtech's M&A market, and emerging partnership models
- The medtech industry's evolution and convergence with new advanced technologies

Moderator: **Tim Mitchell**, VP Strategic Programs, NAMSA

Wilfred Van Zuilen, President EMEA, Zimmer Biomet

Xavier Bertrand, VP Healthcare Services and Alliances, Boston Scientific

Thomas Hummel, Digital Transformation Corporate Development, Fresenius Kabi

Medtech Agenda

10:30 Morning Break

11:00 The Rise Of Business Development Opportunities Within Medtech & How Increased Innovation Is Catapulting Investment Into The Mainstream

The dearth of medtech deals in 2020 and 2021, combined with the pile up of cash reserves amongst leading players and interest from PE, shows promise for a healthy 2022. With non-emergency procedures deferred during the pandemic, a backlog of activity should power growth for medtech businesses. With the IPO market wide open and a buoyant stock market driven by SPACs growing medtech business have prospects for dual-track exit processes. A panel of medtech companies and stakeholders involved in recent mergers or acquisitions discuss the challenges of the current M&A market, the trend toward larger consolidation deals as well as bolt-on acquisitions, the increased activity of private equity, and the implications for innovation in the sector.

- BD and partnering strategies from the top medtech commercial leaders
- New areas of interest for potential new and exciting deals
- The current medtech M&A landscape and drivers behind this
- What are the most significant challenges medtech innovators encounter on the way to acquisition—where are the crucial inflection points in the journey?
- Has a shrinking number of potential buyers created a greater challenge for innovators looking to be acquired?
- How has the pattern of larger medtech players outsourcing R&D to external innovation impacted valuations for start-ups? What ramifications does this have for M&A volume and profitability?

Moderator: **Gunnar Sachs**, Partner, Clifford Chance

Charity Kufaas, VP BD and Strategy, Medtronic

Antonio Sanchez-Cordero, VP Business Development (M&A) Peripheral Intervention, BD

Rupert Winckler, Head of BD EMEA, Olympus

Thomas Hummel, Digital Transformation Corporate Development, Fresenius Kabi

Medtech Agenda

11:45 Patients, Providers, Payers And Product - The Pillars Underpinning Medtech Market Access Strategy

With limited budgets and increasing populations, there has been growing pressure on governments to provide the latest healthcare solutions for their countries. Market access planning and strategy has become more important than ever. As a result, healthcare systems around the world must focus on introducing technologies and treatments that can benefit the whole healthcare system, rather than cost reductions in one area alone. A panel of market access experts discuss the value of their devices and the challenges faced with a comprehensive market access strategy for their products.

- Regulatory oversights and the challenges with new products
- Understanding how the adoption journey differs depending on geographical market
- Navigating local and national market access routes to benefit providers, payers and patients

Moderator: **Laurie Rowe**, Director & Founder, RED Medtech

Markus Ott, VP and Head of Global Market Access and Health Policy, Roche Diagnostics

Angela Liedler, Managing Director, Precisis

Frank Maddux, Global Chief Medical Officer, Fresenius Medical Care

Ariana Adjani, Co-Founder, Fine Treatment

12:30 Lunch Break

13:45 The Medtech Investment Landscape – Rebounding, Evolving And Looking Forward

With total revenue of \$510 billion in 2019, the medtech industry is increasing its share of the whole healthcare pie. Accelerated in 2020 & 2021 by the response to the global pandemic, technology has radically prompted disruption in fundamental ways, changing how healthcare is delivered to patients and creating new business models for innovative organisations. Never has the medtech industry been so attractive to investors, with companies showing potential for profitability, resiliency and growth fuelling an influx of capital. A panel of medtech investors discuss the dynamics shaping the industry, the real life implications of relevant trends and how investors and companies alike can ensure success in this ever growing market

- Evolution product models as part of the medtech investment landscape
- Innovative technologies to form part of attractive medtech investment opportunities
- Putting consumers in control to develop a scalable and sellable product
- Where is investment coming from: New funds and strategies within medtech investment

Moderator: **Peter Finnie**, Partner, Potter Clarkson

Brian Hakim, Director of International Business Development, MedtecX

Baudouin Hue, Partner, Karista

Drew Burdon, Partner, EQT Life Sciences

Antoine Pau, Senior Partner, Truffle Capital

Medtech Agenda

14:30 Collaboration & Partnerships As The Route To Success – Creating ‘Beyond The Product’ Partnerships Between Providers And Medtech Players

Healthcare provision is undergoing unprecedented change and posing challenges for existing systems and providers. In Europe the projected gap between public health expenditure and government budgets is increasing and expected to reach 2% of GDP by 2030 in some countries. The opportunity lies in medtech companies working closely with healthcare providers to deliver not just equipment but other innovative services, that meet specific provider needs, offering significant opportunities on both sides.

- The benefits of partnerships, beyond lowering fixed costs and improving service levels
- Untapped revenue stream for medtech companies
- Credibility obstacles with providers and how to overcome them

Moderator: **Seamus Browne**, Head of Industry Partnerships, Royal College of Surgeons

John E. Milad, CEO, Quanta

Sergio Levi, VP and Head of Strategic Alliances, Philips

Bruce Lichorowic, President & CEO, Galen Robotics

15:15 Afternoon Break

16:00 Risk Reduction And Value Creation In Medtech Product Development - The Critical Role Of Preclinical Evaluation For Innovators, Investors And Stakeholders In The Healthcare Ecosystem

Innovation drives the advancement of health care. Far from a random moment of inspiration, successful innovation follows a disciplined development path. Before new technologies can reach the clinic, careful planning to define and complete the right preclinical studies with the right models is vital to satisfy the needs of key stakeholders and propel the program to the next stage. It is a pivotal phase of development that reduces risk and uncertainty while creating significant value. Join this session as we discuss the importance of innovation and all that it entails.

- Key elements of the preclinical phase in Med Tech innovation
- The vital importance of pathology evaluation, especially prior to final GLP studies
- Observations on some of the latest trends in Med Tech and cutting-edge innovations coming through our lab

Robert Kieval, EVP Strategic Partnerships, Veranex

Medtech Agenda

16:20 A Western Perspective On Crossborder Medtech Transactions With China

With the rapid growth of Chinese MedTech champions combined with a continued push for innovation, cross-border deals are increasingly playing a meaningful role in fueling innovation in China. However these deals, in light of the rapidly evolving landscape of leading players, local priorities and regulatory changes, are not without their challenges. This panel will feature Western MedTech executives with China experiences sharing their views of the China opportunities and challenges in order to help forge a successful pathway forward for Western MedTechs to capitalize on the China opportunity.

Moderator: Ari Silverman, Partner, Mavie Technologies
Jose (Pepe) Callo Gordo, Operating Partner, Valiance
Georg Bortlein, Founder & President, High Life
Hamman de Vaal, Chief Commercial Officer, AdjuCor

17:00 Nothing Ventured Nothing Gained – Corporates Deploying Capital With Surgical Precision

Corporate venture capital is playing an increasingly crucial role in the medtech funding landscape and funds are more active than ever. An analysis of corporate investment trends showed medtech companies with investment units participated in rounds worth \$1.2bn in the first three quarters of 2020. For the start ups, it still seems that corporate funds can be as, or more, risk averse, than traditional VCs but the prevalence of CVCs in new rounds is undeniable. A panel of leading CVC investors from multiple sectors consider the developing role of corporate and strategic capital in supporting innovation, and how SMEs can attract and engage with the corporate capital.

- *The role of the pandemic in the sectors growing interest in funding early stage device makers*
- *Is the involvement of CVC in early stage funding likely to increase, or will the most CVC funding continue to focus on development of regulatory, reimbursement, and commercialisation pathways for more established medtechs?*
- *What key factors would compel CVC to invest in an early stage medtechs, how much clinical data is necessary, and how can companies refine their pitch to attract strategic funding?*

Moderator: Carina Tyrell, Chief of Staff & Investment Associate, Walden Catalyst Ventures
Oliver Keown, Managing Director, Intuitive Ventures
Gadi Toren, Investment Partner, Robert Bosch Venture Capital
John Lee Allen, Managing Partner, RYSE Asset Management

17:45 Drinks Reception

18:30 Networking Party @ The Cherkin

Medtech Agenda

Wednesday, 11 May – Main Agenda

09:00 LSX Welcome Address

09:15 Keynote Presentation: Making Innovation Happen

The rate of change and innovation in the world is accelerating, but how do you keep up as a business, particularly in a highly regulated environment like the medtech industry? What are executional ways to accelerate engineering innovation within your business and tackle the hurdles the world throws at you? RPD International develops and manufactures hundreds of products across a wide range of industries, including a particular focus on medical devices. Take insights from how these businesses are able to deliver new products that have true impact in a supply chain environment that seems to be ever worsening.

- *How to build a real process for delivering on innovation in your business*
- *How to build products that customers really want and patients really need*
- *How to plan amongst the current global supply chain disruption*

Josh Valman, CEO, RPD International

Medtech Agenda

09:45 The Devil Is In The Data: How The Medtech Sector Is Optimising Its Data Assets And Connecting With Consumers In A Wholly Patient Centric Approach

The surge in innovative medical technologies and devices in recent years has elevated patients to true stakeholders in the medtech ecosystem. Medical technology is gathering data around the clock all over the world, and this presents a massive opportunity for companies big and small to enhance their commercial strategies by better understanding the patients whom their products are serving. It is now imperative for device manufacturers, diagnostic companies, and health systems to design their products with the patient experience in mind: comfort, convenience, and connectivity all now constituting essential traits of a successful medical technology. Throw innovative technologies like AI and analytics into the mix, and the insights derivable from clinical, device and life-style data expand exponentially, as do the possibilities for their use. But is the medtech sector truly optimising its data assets and how are medtech manufacturers and innovators ensuring that patient-centricity is truly built into their products? A panel of medtech innovation leaders discuss.

- Unlocking the full potential of health data, and new applications in 2022
- Information is power: ethical data use and the importance of patient transparency
- Regulatory and legal challenges limiting data access and the development of new solutions for treating patients and advanced treatments
- How is the MDR going to look at data

Moderator: **Jérôme Stevens**, General Manager & co-founder, Webhelp Medica

Marc Julien, Co-CEO, Diabeloop

Laurent Vandebrouck, CEO, Chronolife

Eliane Schutte, CEO, Xeltis

Ian Crosbie, CEO, Sequana Medical

10:30 Morning Break

11:00 Understanding The Challenges The Medtech Sector Is Facing As A Result Of The New EU Regulations & The UK's Withdrawal From The EU

- The Future of Legacy Devices under the new Medical Device Regulation (MDR)
- The key changes brought about by the In Vitro Diagnostic Regulation (IVDR) and the challenges the Diagnostic Industry might face
- Understanding the impact of the UK's withdrawal from the EU on the MedTech Industry

Tina Amini, Medical Device Division Director, NDA Group

Medtech Agenda

11:20 Navigating & Identifying The Pitfalls & Unforeseen Regulatory Complications Within The Context Of A Pandemic

Before the COVID-19 pandemic stole the show, the upcoming Medical Device Regulation and In Vitro Diagnostic Regulation were causing much concern in Europe's markets, with timelines putting pressure on many companies and fears that an insufficient number of notified bodies would be designated by the necessary juncture. And while the disruption caused by the pandemic has pushed the MDR and IVDR deadlines back, it has also introduced many fresh challenges which the sector must be ready to confront. A panel of experts from leading medical device and diagnostic stakeholders discuss the current outlook for the regulations and how the sector can prepare itself.

- The long term impact of travel restrictions on MDR/IVDR conformity assessments
- Virtual audits as a solution to a 21st century problem
- IVDR: A risk of shortages of tests?
- Notified bodies as a key pillar within the medtech regulatory system: Capacity vs workload

Moderator: **Stephen Reese**, Partner, Clifford Chance

Juliette Cook, Vice President Quality & Regulatory Affairs, Implantica

Claire Woodthorpe, COO and VP Europe, Lightpoint Medical

Tina Amini, Medical Device Division Director, NDA Group

12:00 Making The Leap – What Does It Take To Be The Next Meddev Success Story?

Over the past two years, the medical device industry has faced unprecedented challenges ranging from the COVID-19 pandemic, supply chain disruptions, and rapid regulatory changes. However, the market continues to grow and is projected to be over \$603 billion by 2023 worldwide with rapid expansions in digital health, the Internet of Medical Things (IoMT), robotics, public health, and a wave of technology advancements from 3D printing, AI and machine learning to bio batteries, wearables, and nanomedicine. We are entering a leapfrog phase in medical device development--exciting and unprecedented opportunities for innovative companies to lead and change the health of the world. Join this session for a deep dive into a year-on-year study of the state of the medical device industry, looking at the trends from before, during, and beyond the pandemic as we consider the future of medical devices

- What does it take to be a medical device leader?
- How do innovative companies navigate complex processes, meet regulatory requirements, build resilient talented teams and supply chains, and develop quality products for patients?
- What are the key success factors medical device companies need to master at each stage from ideation to commercialization and scale?

Brittanie Campbell, Account Executive, Greenlight Guru

Medtech Agenda

12:20 Digitisation Of Medtech – A Key Role In The Transformation Of Healthcare

Digital technology in the medtech space has the potential to capture huge value in healthcare systems around the world, with the benefit of improving care whilst also driving down costs. Thanks to a range of digital and date interventions, it is estimated cost savings could lie anywhere between an estimated \$1.5 trillion and \$3 trillion a year by 2030. However despite the increased adoption of digital interventions during the pandemic, many medtech companies have been slow to prepare for the new digital world of healthcare. A panel of experts discuss the exciting new opportunities for medtech companies and how best to take advantage of them.

- Driving new sources of growth and improving patient care through digital solutions
- How digital technology in medtech will best serve patients
- Embracing new capabilities and operating models
- Considering the complete operating ecosystem when designing digital driven solutions

Moderator: **Elizabeth Cairns**, Medtech Reporter, Vantage

Diana Saraceni, Managing Partner, Panakès Partners

Gil Rabbie, Digital Solutions & Capability Development Leader, Boston Scientific

Per Vegard, CEO, CMR Surgical

Jonathan Wood, Regional Director, Abbott Vascular

13:00 Lunch Break

14:00 The Future Of Value-Based Healthcare & The Medtech Drivers In Its Creation

Health care delivery has been transformed over the past decade and medtech companies are driving its future. Following the global Covid-19 pandemic there has been extra impetus for system-wide change. A multi-stakeholder panel consider the differing definitions of value which are driving decision-making and deal-making across the medtech sector, the developing role of SMEs, providers, payers, and commercial leaders in creating superior clinical and economic outcomes across the medtech value chain, and how VBC can create a sustainable global health system, relieve funding pressures and deliver superior care.

- Move to long term value based healthcare, offering products that protect from price erosion, focus on the customer and increase market share
- Understanding the clinical context that devices are used in, to deliver wellness solutions
- New funding models and payment models within medtech
- Data use and interoperability, working with providers to manage AI-ethics, data privacy and cyber security
- Trust and transparency within multinationals, to foster collaboration

Moderator: **Zina Fragkiadaki**, Senior Reporter, HealthInvestor UK

Laura Niklason, CEO, Humacyte

Giles Hamilton, CEO, ODX Innovations

Medtech Agenda

14:40 Challenges & Considerations In Planning And Conducting A Clinical Study

- Planning the most appropriate path to market
- Alignment of protocol with regulation and guidelines
- The challenges of submissions
- Common pitfalls – an interactive Q&A

Linda Korthout, Director International Clinical Affairs, MCRA

Peter Bowness, Director, International Regulatory Affairs, MCRA; Former Senior Regulator, BSI

15:20 Going Beyond Solving Unmet Needs - The Role Of Product Design In Successful Medtech Commercialisation

Major advances in technology are driving innovation within healthcare, but at the heart and beginning of this journey, remains the product. Where once it was enough to create a solution to a problem, companies and innovators now need to look to the future from the very start in order for a product to ultimately succeed within an evolving and competitive market. A panel of specialists discuss the pitfalls and nuances within product design and the importance of always looking ahead

- The importance of complete product lifecycle planning
- Current and future manufacturing and supply chain challenges
- Early commercial planning and building this into your product design strategy

Moderator: **Carl Hewett**, Head of Medical Design Innovation, Sagentia Innovation

Luke Hares, CTO, CMR Surgical

Susanne Schorsch, Vice President Business Development, Comphya

Mike Harris, CEO, Biocomposites

16:00 Close Of Congress

Medtech Agenda

Wednesday, 11 May – Satellite Sessions

11:00-12:45



Co-hosted by:



Improved 1-2-1 partnering

The LSX World Congress will feature our state-of-the-art 1-2-1 partnering system! App-based, and allowing you to schedule, move and confirm meetings 'on the fly', your partnering experience will be transformed!

Maximise your out-of-session networking time and secure those vital face-to-face meetings. The partnering system will go live with your profile filled in from the information provided on registration and allow you to search for potential partners and book meetings in the extensive 1-2-1 partnering area.

The partnering system will go live around three weeks prior to the event. Start the new year with a bang by meeting your next industry partners!



Female Founders **meet up**



Monday 9th, May 14:45-18:00

Goodwin Procter London, 100 Cheapside, London, EC2 6DY

14:45	Arrival
15:00	Welcome address
15:10	Presentation (speaker TBC)
15:40	Coffee break and networking
16:00	<p>Fireside chat: What makes a great leader?</p> <p><i>Some of the industry's most experienced and respected women share their thoughts on leadership, including what makes a great leader, where women get it so right and how to increase the representation of women in leadership within health and life science.</i></p> <p>Annalisa Jenkins, <i>Chairman of the Court, London School of Hygiene & Tropical Medicine</i> Emma Sceats, <i>CEO, Isogenica</i> Priya Mande, <i>Interim CEO, PsiOxus Therapeutics</i> Moderator: Sophie McGrath, <i>Technology & Life Sciences Partner, Goodwin Procter</i></p>
16:45	Networking drinks
18:00	Wrap up

Investor syndication **networking**



Monday, 9 May 18:00-22:00

The Alchemist Bar. London

Join your investor peers in an evening networking session like no other, at The Alchemist Bar, a mixologists haven, just a stone's throw from the conference venue on Monday, 9 May.

Attendees are invited to join their peers from 6.00pm at the exclusive venue, for an evening designed to help you informally connect with investor peers to discuss syndication opportunities over award winning cocktails, wines and spirits in this exclusive subterranean space.



Pre-Event networking party

The networking party takes place on Monday, 9 May, from 18:00. Attendees can choose to add what will be a fantastic night of networking and refreshments to their ticket at registration, and get their event relationship building off to the best possible start.

155 metres above the city, City Garden @ Sky Garden is one of the most unique rooftop locations in the capital. Renowned for its beautiful landscaped gardens, innovative architecture and unrivalled views, the City Garden offers uninterrupted views of the London skyline.



Networking party - SOLD OUT

The day 1 networking party takes place Tuesday, 10 May, from 18:00. Attendees can choose to add what will be a fantastic night of networking and refreshments to their ticket at registration, and double down on their event relationship building after the pre-event networking reception.

Searcys at the Gherkin, with its iconic dome roof and panoramic views impresses from every angle. Adorning one of London's most iconic skyscrapers. Another incredible opportunity for networking in one of London's most well known landmarks.

Searcys at the Gherkin is another perfect venue to wow your clients..









Delegate Packages

In Person	05-Nov-21	26-Nov-21	18-Feb-22	11-Mar-22	01-Apr-22	22-Apr-22	Final Price
Qualified & Active Investor (T&Cs apply)	Free	Free	Free	Free	Free	Free	£395
Bio / Med / Health...Tech	£995	£1,175	£1,295	£1,445	£1,595	£1,745	£1,995
Bio / Med / Health...Tech + Showcase	£1,995	£2,175	£2,295	£2,445	£2,595	£2,745	£2,995
Pharma / Medtech / Big Tech Commercial Leader	£995	£1,175	£1,295	£1,445	£1,595	£1,745	£1,995
Professional / Financial / Contract Services	£1,345	£1,655	£1,845	£2,045	£2,345	£2,645	£2,995

To book your place please visit: www.lsxleaders.com/world

Why sponsor

The Congress offers a limited number of opportunities for those that wish to raise their profile, showcase their solutions, enhance their brand, demonstrate thought leadership and access and engage with leaders across the life sciences ecosystem. We are presenting tremendous opportunities for top tier companies who would see the congress as a platform to:

-  **Demonstrate thought leadership and position your organisation at the forefront of the life sciences and healthcare industry**
-  **Co-host a leadership forum or workshop to connect directly with a pre-qualified group whose businesses you can help advance**
-  **Educate potential new clients and partners about your unique offering, service or solution**
-  **Be seen as an obvious partner of choice in your specific area of expertise**
-  **Access and develop meaningful relationships with decision makers**
-  **Exhibit or showcase your technology or offering to a large high calibre group of global life science executive leaders, investors and influencers**

For sponsor or exhibition enquiries contact Tom Roberts tom@lsxleaders.com

Sponsorship Packages

Benefits	Platinum	Gold	Silver	Bronze	Booth
20 min keynote presentation in plenary	Yes				
15 min non-plenary presentation		Yes			
Host an exclusive forum / workshop	Yes	Yes	Yes		
Speaking role on a non-plenary panel discussion	Yes	Yes	Yes		
Logo on event signage and display boards	Yes	Yes	Yes	Yes	
Logo on LSX World Congress main website	Yes	Yes	Yes	Yes	Yes
Logo on emails sent to LSX Database	Yes	Yes	Yes	Yes	
Company literature on media desk	Yes	Yes	Yes	Yes	Yes
Exhibition networking booth					Yes
Pre-event marketing and brand exposure	Yes	Yes	Yes	Yes	Yes
Branding across event website	Yes	Yes	Yes	Yes	Yes
Number of passes for content and 1:1 partnering	4+	3	2	2	2
Investment Level	£££	£££	££	££	£

Talk to me about additional opportunities including:

- Drinks reception
- Dinner host
- Coffee & networking area
- Lanyards
- 1-2-1 partnering area
- App
- WiFi
- Showcase zone
- VIP Lounge
- Charging stations

Networking Drinks Sponsorship Package

Benefits	Sole Host	Syndicate Host* (1 of 2)	Syndicate Host* (1 of 4)
5min welcome remarks at Networking Party venue	Exclusive	Joint	None
Prominent onsite branding	Exclusive	Joint	Joint
Digital Gobo signage above bar area	Exclusive	Joint	Joint
Networking Drinks Lanyard branding	Exclusive	Joint	Joint
Logo on LSX World Congress main website	Yes	Yes	Yes
Pre-event marketing and brand exposure	Yes	Yes	Yes
Welcome remarks in onsite guide	Yes	Yes	Yes
Number of guest passes allocated from total attendees	100	50	25
Investment Level	££££	££	£

* Please note, a Syndicate Host must bring the requisite number of fellow syndicate sponsors for this package to be offered

Talk to us about additional opportunities including:

- Dinner host
- Coffee & networking area
- Lanyards
- 1-2-1 partnering area
- Onsite App
- WiFi
- Showcase zone
- VIP Lounge
- Charging stations

Industry Leading Events



26-27 April 2022
London, UK
www.longevityleaders.com



18-19 October 2022
BCEC, Boston, USA
www.lsxleaders.com/rna



10-11 May 2022
London, UK
www.lsxleaders.com/world



14 November 2022
London, UK
www.lsxleaders.com/investival



21-22 June 2022
Boston, USA
www.lsxleaders.com/usa



European Lifestars Awards
14 November 2022
London, UK
www.lsxleaders.com/lifestars



6-7 September 2022
Copenhagen, Denmark
www.lsxleaders.com/nordic




15-16 March 2023
Congress Center Basel, Switzerland
www.lsxleaders.com/rna

LSX World Congress 2021 Summary

The 7th LSX World Congress grew significantly in terms of the overall numbers and diversity of the delegation.


The international investor attendance was over 600, and we welcomed the most exciting life science and healthcare companies from across the world; from the newest innovative start-ups to leading public corporates.

The following stats represent the diversity of our audience.



2021 All Attendees


All Tech



Investors




Pharma




2021 All Tech Attendees


Region




Preferred Investor/Strategic Source



Sector Focus




Company Stage




2021 All Tech Attendees


Pipeline Stage Biotech



Pipeline Stage Healthtech / Medtech / Deeptech




Deals Considered




2021 Investor Attendees


Region





Type of Investor/Strategic



Sector Interest



2021 Investor Attendees



Contact Us

For biotech, healthtech, medtech and general enquiries contact:

Josh Dance, SVP
josh@lsxleaders.com
 +44 (0) 203 637 5908

For sponsor enquiries contact:

Tom Roberts, VP, Business Development
tom@lsxleaders.com
 +44 (0) 203 637 5908

Or visit us at www.lsxleaders.com/world